Previous close | 524.30 |
Open | 535.65 |
Bid | 530.10 x 0 |
Ask | 0.00 x 0 |
Day's range | 524.30 - 537.50 |
52-week range | 489.00 - 596.35 |
Volume | |
Avg. volume | 81,087 |
Market cap | 941.396B |
Beta (5Y monthly) | 0.24 |
PE ratio (TTM) | 52.65 |
EPS (TTM) | 10.09 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | 5.50 (1.04%) |
Ex-dividend date | 10 Nov 2023 |
1y target est | N/A |
Consumer goods maker Dabur India flagged sluggish demand in the March quarter and indicated slowing revenue growth from prior quarters on Thursday, sending shares to a near six-month low. Dabur said it expects mid-single digit percentage revenue growth in the quarter ended March 31, compared to a 7% rise in the December-quarter and 7.3% jump in the quarter before that. Dabur also forecast double-digit percentage growth in constant currency terms for its international business, led by the Middle East and North Africa (MENA) region, Egypt, and Turkey.
Dabur India said on Wednesday a U.S. court had dismissed two of its three subsidiaries as defendants in a lawsuit tying the use of hair relaxer products to ovarian and uterine cancers as well as other health issues. as defendants "for lack of personal jurisdiction" as neither was involved in manufacturing, marketing, distributing or selling hair relaxer products in the United States, the company said in a late filing on Wednesday. However, Dabur's unit Namaste Laboratories continues to be a defendant along with many other industry players such as L'Oreal, Revlon, Luster Products and Avion Industries among others, it added.
The consumer goods firm said about 5,400 cases against several companies including its subsidiaries, Namaste Laboratories, Dermoviva Skin Essentials and Dabur International, have been consolidated as a multi-district litigation before a U.S. District Court in Illinois. The units have denied liability and have retained counsel to defend them, the company said.